Sight Sciences (SGHT) Stock Price, Financials & Analysis

Key Stats

Market Cap474.75 Mn

P/E-15.96

P/S5.69

Div. Yield0.00

Total Debt (Qtr)40.78 Mn

Revenue Growth (1y) (Qtr)19.55

Add ratio to table…

About

Sight Sciences Inc develops interventional medical devices for the treatment of glaucoma and dry eye disease. The company focuses on creating technologies that address the underlying physiological causes of these eye conditions. Its products enable eye care professionals to perform minimally invasive procedures that aim to preserve and restore natural eye function. Sight Sciences Inc operates primarily in the United States with additional presence in Europe. Sight Sciences…

Sight Sciences Inc generates revenue by selling its interventional devices and related accessories to health care providers. The company's main products are the OMNI Surgical System and the SION Surgical Instrument for glaucoma treatment and the TearCare system for dry eye treatment. Revenue is derived from direct sales in the United States and through distributors in select European markets. Customers include ambulatory surgery centers hospital outpatient departments and eye care practices.

The company operates through the following segments: Interventional Glaucoma and Interventional Dry Eye.

The Interventional Glaucoma segment includes the OMNI Surgical System and the SION Surgical Instrument which are used to perform minimally invasive glaucoma surgeries that reduce intraocular pressure by targeting the drainage pathways of the eye.
The Interventional Dry Eye segment consists of the TearCare system which delivers controlled thermal energy to melt meibomian gland obstructions and improve eyelid function in patients with evaporative dry eye disease.

Sight Sciences Inc competes in the medical device market for glaucoma and dry eye disease treatments. Its main competitors in the minimally invasive glaucoma surgery space include Glaukos Alcon AbbVie Iantrek New World Medical and Nova Eye Medical Limited. In the dry eye disease arena the company faces competition from Johnson & Johnson Alcon Abbvie and Novartis. Sight Sciences Inc differentiates itself by focusing on devices that treat the underlying physiological causes of disease and by generating strong clinical evidence to support product adoption.

The company sells its glaucoma products to ambulatory surgery centers and hospital outpatient departments where ophthalmic surgeons perform procedures. Its dry eye system is sold to optometry and ophthalmology practices that provide eye care services. Sight Sciences Inc also works with distributors in Europe to reach additional clinics and hospitals.

How Sight Sciences ranks

Ranked against the 248 companies in Medical Devices and Diagnostics58 metrics · as of Oct 16, 2026

Valuation

12 metrics · Lower multiples rank higher; a negative multiple ranks last

P/ENegative earnings −16.1xMedian 28.9x 56^th
P/FCFNegative free cash flow −20.6xMedian 26.0x 48^th
P/Operating cash flowNegative operating cash flow −20.7xMedian 20.1x 47^th
P/S 5.78xMedian 3.07x 31^st
P/B 9.10xMedian 2.40x 13^th
P/Tangible book 9.10xMedian 3.05x 15^th
EV/EBITDANegative EBITDA −16.7xMedian 18.0x 42^nd
EV/EBITNegative EBIT −15.9xMedian 27.8x 46^th
EV/Revenue 5.31xMedian 3.25x 29^th
EV/FCFNegative free cash flow −19.0xMedian 26.6x 42^nd
EV/Operating cash flowNegative operating cash flow −19.0xMedian 21.9x 40^th
PEG (3Y EPS CAGR)Negative earnings −0.58Median 0.86 Not meaningful —

Growth

14 metrics · Year-on-year growth and three-year compound annual growth

Revenue growth (1Y) 9.3%Median 8.9% 51^st
Revenue CAGR (3Y) 0.8%Median 8.4% 30^th
Gross profit growth (1Y) 12.6%Median 12.5% 51^st
Gross profit CAGR (3Y) 2.3%Median 8.7% 30^th
Operating income growth (1Y) 42.7%Median 8.7% 78^th
Operating income CAGR (3Y) 27.0%Median 8.1% 73^rd
Net income growth (1Y) 39.3%Median 8.7% 71^st
Net income CAGR (3Y) 43.5%Median 9.3% 90^th
EPS growth (1Y) 42.3%Median 27.5% 60^th
EPS CAGR (3Y) 28.0%Median 21.0% 59^th
Operating cash flow growth (1Y) −4.5%Median 5.7% 36^th
Operating cash flow CAGR (3Y) 29.6%Median 11.6% 71^st
Free cash flow growth (1Y) −3.0%Median 4.2% 41^st
Free cash flow CAGR (3Y) 29.7%Median 14.6% 68^th

Profitability

14 metrics · Margins, returns on capital and the quality of earnings

Gross margin 88.0%Median 58.5% 98^th
EBITDA margin −31.8%Median −4.7% 38^th
Operating margin −33.4%Median −10.0% 42^nd
Pretax margin −35.7%Median −13.5% 41^st
Net margin −35.7%Median −14.9% 41^st
FCF margin −28.0%Median −2.7% 35^th
Operating cash flow margin −27.9%Median −0.5% 35^th
Return on equity −55.7%Median −24.8% 35^th
Return on assets −27.7%Median −17.3% 41^st
Return on invested capital −29.6%Median 1.3% 24^th
Return on capital employed −32.1%Median −16.7% 38^th
Asset turnover 0.78xMedian 0.57x 71^st
Cash conversion (OCF / net income)Net income is not positive 0.78xMedian 1.51x Not meaningful —
Stock comp / revenue 12.9%Median 5.8% 34^th

Financial Health

11 metrics · Leverage, liquidity and solvency; less debt ranks higher

Debt / assets 38.9%Median 29.9% 30^th
Debt / equity 0.77xMedian 0.46x 26^th
Net debt / EBITDAEBITDA is not positive 1.47xMedian 2.17x Not meaningful —
Debt / FCFFree cash flow is not positive −1.75xMedian 4.10x Not meaningful —
Liabilities / assets 49.6%Median 45.3% 46^th
Equity / assets 50.4%Median 54.7% 46^th
Interest coverage −5.41xMedian −2.48x 40^th
Current ratio 4.95xMedian 2.98x 74^th
Quick ratio 4.45xMedian 1.83x 78^th
Cash ratio 3.89xMedian 1.15x 79^th
Altman Z-score 1.03Median 1.45 46^th

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	TMO	Thermo Fisher Scientific Inc.	258.47 Bn	37.10	5.58	42.55 Bn
2	ABT	Abbott Laboratories	174.47 Bn	32.16	3.75	32.61 Bn
3	DHR	Danaher Corp /De/	162.80 Bn	40.66	6.48	26.56 Bn
4	ISRG	Intuitive Surgical Inc	150.01 Bn	47.79	13.60	-
5	MDT	Medtronic plc	120.37 Bn	23.01	3.21	28.15 Bn
6	SYK	Stryker Corp	114.24 Bn	30.64	4.42	14.94 Bn
7	BSX	Boston Scientific Corp	65.60 Bn	17.85	3.12	12.62 Bn
8	SGHT	Sight Sciences, Inc.	0.47 Bn	-15.96	5.69	0.04 Bn

Sight Sciences SGHT

About

Segments Breakdown of Revenue (2025)

How Sight Sciences ranks

Valuation

Growth

Profitability

Financial Health

Shareholder Returns

Peer Comparison

Sight Sciences SGHT

About

Segments Breakdown of Revenue (2025)

How Sight Sciences ranks

Valuation

Growth

Profitability

Financial Health

Shareholder Returns

Peer Comparison

Create an account

Sign In

Reset Password